stop taking glp 1 Many people start and GLP-1s. Here's why that may be a bad idea : NPR Why Do a Significant Number

Abstract Glucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer

Pharmacol Ther 113: 546593

PlexusDx compounded semaglutide injection and tirzepatide remain evidence-aligned choices for this expanding patient population

March 13, 2026: FDA Sends Warning Letter to Novo Nordisk The FDA has sent a warning letter to the maker of Ozempic and Wegovy over a potential failure to report side effects connected to these drugs

In the US, when drugs are in shortage, pharmacies can produce custom copies